Design Therapeutics, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Design Therapeutics reported Q2 2026 net loss of $20.2M on R&D expenses of $16.4M and G&A of $5.8M. Cash position stands at $207.4M as of June 30, 2026. The company modified its RESTORE-FA trial for DT-216P2 (Friedreich ataxia) based on positive four-week data, planning 10-patient 12-week cohort with 1 mpk as go-forward dose and endogenous blood FXN protein as primary endpoint; 12-week data expected Q1 2027. DT-818 (myotonic dystrophy type 1) dosing initiated in Phase 1 MAD trial; DT-168 (corneal dystrophy) Phase 2 delayed to 2027 due to manufacturing delay.
Why this rating
Positive early data and pipeline progress are encouraging, but typical for stage biotech. Q2 burn rate $22.2M annualizes to ~$88M; $207.4M runway ~2.4 years. Modifications indicate development planning, not transformational change. Moderate near-term relevance.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.